Basilea Pharmaceutica - Revenue upside surprise for 2022
Basilea has announced preliminary, unaudited revenue results for FY22, together with an operational update on its commercial and pipeline assets....
327 Views
Basilea Pharmaceutica - Cresemba milestone payment triggered
Basilea has announced that it has received a sales-related milestone payment of CHF20m from its US licensing partner Astellas Pharma. This was...
430 Views
Basilea Pharmaceutica - Third leg of strategy executed with debt repayment
Basilea has announced the full repayment of the CHF113.8m outstanding amount under its 2.75% convertible bonds due on 23 December 2022, supported...
671 Views
Basilea Pharmaceutica - Oncology milestone payment triggered
As expected, Basilea continues to derive value from its oncology exit as it has received a transition-related milestone payment of US$4m (CHF3.7m)...
671 Views
Basilea Pharmaceutica - Third oncology asset sale announced, as planned
Basilea announced another successful oncology asset sale as a part of its strategic plan to focus on its core anti-infectives business. The company...
336 Views